Health Robotics’ Announces Memorial Care’s [CA] 57% Savings From Ameridose’s Switch to i.v.STATION Robot
Bozen, Sud-Tirol, Italy – August 12th, 2013.
Health Robotics recently announced that Memorial Care Health System in Long Beach released to Health Robotics’ User Group an ROI study focused on 57% average savings as a result of insourcing Sterile Compounding patient doses on the i.v.STATION Robot, compared to its prior equivalent costs with Ameridose.
Ed Wong, Director of Pharmacy at Memorial Care’s Miller Hospital stated: “Just as an example of the i.v.STATION Robot cost benefits at Memorial Care, for a single active pharmaceutical principle [Oxytocin], we documented savings of $73,874 (or 60%) over a 21 month period between August 2011 and April 2013. i.v.STATION utilized standard commercially-available Baxter Viaflex Bags and APP drug vials of 10ml and 30ml, with the Robot preparing dilutions of 13,876 patient doses of 1 Liter Bags LR, and 3,955 patient doses of 500ml IV Bags at 0.9% NS, at an internal cost of $49,954 compared to the prior and equivalent Ameridose expense of $123,828.”
Under the current leadership of William Churchill from Brigham & Women’s Hospital and Paul Bush from Duke University Medical Center, Health Robotics’ User Group holds teleconferences once per quarter for its members, in addition to an annual meeting during ASHP Midyear, which provides an ideal forum for progressive Health-System Pharmacies to compare experiences, best practices, and cost savings, on how to improve Sterile Compounding quality and lower costs.
Gaspar DeViedma, Health Robotics’ Executive Vice President stated: “I’m very proud that i.v.STATION continues on its undeterred path to collect under-12 month ROIs and cost justifications from both Academic and Community Health-Systems pharmacies in North America, following prior similar published reports from Brigham & Women’s Hospital [MA], LeeSar Compounding Services [FL], Allegiance Health [MI], Candler Hospital [GA], St. Joseph Hospital [GA], and several others.
These documented benefits are especially important in the wake of the recent legislative attempts in Massachusetts [ground zero for 2012 deadly contamination affecting patients nationwide], www.jeffreysanchez.org/compounding-pharmacy- bill-report/, and the appalling results of FDA’s 2013 inspection reports at 50 sites: www.fda.gov/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPol icy/ORA/ORAElectronicReadingRoom/ucm340853.htm
Download in PDF Format :